Response assessment of hormonal therapy in prostate cancer by [11C] choline PET/CT

Clinical Nuclear Medicine

Volumn 35, Issue 9, 2010, Pages 701-703

  De Waele, Alexandra ^a   Van Binnebeek, Sofie ^a   Mottaghy, Felix M ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE C 11; FLUTAMIDE; LEUPRORELIN;

ADULT; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENITIS; MALE; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PROSTATE ADENOCARCINOMA; TREATMENT RESPONSE; UROSEPSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; CARBON RADIOISOTOPES; CHOLINE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77955973599     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181e9faf5     Document Type: Article

References (10)

1. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer; European Association of Urology. Eur Urol. 2008;53:68-80.
2. Moul JW, Sun L, Hotaling JM, et al. Age-adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol. 2007;177:499-503; discussion 503-504.
3. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of-11C-choline positron-emission/computed tomography in patients with increasing prostatespecific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786-793.
4. Takahashi N, Inoue T, Lee J, et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology. 2007;72:226-233.
5. Gutman F, Aflalo-Hazan V, Kerrou K, et al. 18F-choline PET/CT for initial staging of advanced prostate cancer. Am J Roentgenol. 2006;187:W618-W621.
6. Farsad M, Schiavina R, Castellucci P, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642-1649.
7. Husarik DB, Miralbell R, Dubs M, et al. Evaluation of-(18)F-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253-263.
8. Scattoni V, Picchio M, Suardi N, et al. Detection of lymph-node metastases with integrated-11C-choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423-429.
9. Reske SN, Blumstein NM, Neumaier B, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med. 2006;47:1249-1254.
10. Joniau S, Hsu CY, Lerut E, et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol. 2007;51:388-394.